Abstract: Immune checkpoint inhibitors, particularly those targeting PD-1/PD-L1, produce durable responses in a subset of patients across cancer types. Although often well tolerated, these agents can induce a broad spectrum of autoimmune-like complications that may affect any organ system. Treatment of these toxicities primarily consists of immune suppression with corticosteroids and other agents. This review briefly discusses the mechanisms of immune-related adverse events, overviews the clinical and pathologic features of major toxicities caused by PD-1/ PD-L1 blockade, and reviews their management.
I
mmune checkpoint inhibitors (ICIs) have transformed the treatment of numerous cancers including melanoma, non-small cell lung cancer (NSCLC), urothelial cancer, renal cell carcinoma, Hodgkin lymphoma, and head and neck cancer. 1 These agents include monoclonal antibodies that target the PD-1 (pembrolizumab, nivolumab) and one of its ligands, PD-L1 (atezolizumab, durvalumab, avelumab), as well as the cytotoxic T-lymphocyte antigen 4 (CTLA-4) inhibitor ipilimumab. The toxicity profile of these novel agents is quite distinct from conventional cytotoxic chemotherapy agents and in general is somewhat more tolerable. While ICIs do not cause alopecia or myelosuppression or have the emetogenic potential of other anticancer agents, they can induce immune-related adverse events (irAEs), which can affect almost any organ, and range from asymptomatic to fulminant (Fig. 1) .
The triggers of irAEs are incompletely catalogued but seem related to the drugs' mechanism of action. PD-1 is an immune inhibitory checkpoint expressed on the surface of activated T cells. When PD-1 engages its ligands, PD-L1 and PD-L2, T cells become functionally exhausted. This interaction is particularly important in the peripheral tissues and at sites of ongoing inflammation, including the tumor microenvironment.
2 Anti-PD-1/PD-L1 agents block the PD-1-ligand interaction and reinvigorate these quiescent T cells. The resulting T-cell response can effectively treat cancer but may also cause an autoimmune or inflammatory response in normal tissue resulting in irAEs. It remains unclear why particular patients or specific organs are affected in some patients and not in others. Hypotheses include genetic predisposition (similar to certain autoimmune disorders), environmental insults inducing subclinical inflammation, or shared antigens between tumor and affected tissue. [3] [4] [5] Full discussion surrounding the pathogenesis of irAEs is beyond the scope of this review, and the remainder focuses on clinical aspects of immune toxicity. First, we review the clinical and pathologic features of organ-specific irAEs and then follow with a discussion of treatment algorithms.
CLINICAL AND PATHOLOGIC FEATURES OF IRAES Pneumonitis
Pneumonitis is defined as focal or diffuse inflammation of the lung parenchyma. Serious events (grade ≥3) occur in fewer than 1% of patients treated with anti-PD-1/L1, but may occasionally lead to deaths. In a large meta-analysis of nearly 4500 patients treated with anti-PD-1 agents, all-grade pneumonitis was reported more commonly in renal cell carcinoma (4.1%) and NSCLC (4.1%) patients than in melanoma patients (1.6%). It also appeared more frequently in patients receiving combination therapy with either anti-CTLA-4 or peptide agents in addition to anti-PD-1 (6.6%) compared with anti-PD-1 monotherapy (1.6%). Pneumonitis-related deaths were rare, but did occur in 4 NSCLC patients receiving anti-PD-1 monotherapy and 1 melanoma patient receiving combined PD-1/ CTLA-4 blockade. 6 The seemingly increased potential for pneumonitis in NSCLC patients may be due to underlying lung disease, smoking history, or tumor burden, and providers should monitor patients closely regardless of tumor histology.
The median time to onset of pneumonitis is 2.8 months after initiating PD-1 therapy but ranges quite broadly from 9 days to 19.2 months. 7 Pneumonitis has a variable presentation in terms of both clinical and radiographic findings, making diagnosis challenging. The most common patient symptoms are cough and dyspnea, although some patients are completely asymptomatic at diagnosis. Other causes of cough and dyspnea must be considered including infection, pulmonary embolism, and exacerbation of underlying lung disease (e.g., progression of malignancy, worsening of chronic obstructive pulmonary disease, etc.).
Computed tomography (CT) is generally needed to establish the diagnosis. A spectrum of radiographic features has been described, including ground-glass opacities, reticular opacities, cryptogenic organizing pneumonia (COP), acute interstitial pneumonia/ acute respiratory distress syndrome, nonspecific interstitial pneumonia, and hypersensitivity pneumonitis. Ground-glass opacities and COP are the most commonly described CT findings. The radiographic pattern has also been associated with the grade of pneumonitis. For patients with the nonspecific interstitial pneumonia/ hypersensitivity pneumonitis, COP, and acute interstitial pneumonia/ acute respiratory distress syndrome patterns, the median values of grades of pneumonitis were 1, 2, and 3, respectively. Computed tomography involvement of pneumonitis has also been described as more extensive in patients with NSCLC than in patients with melanoma or lymphoma. 8 Given the potential severity of pneumonitis, patients should be closely monitored for symptoms of cough or dyspnea with a low threshold for cross-sectional chest imaging. Following treatment (see TREATMENT ALGORITHMS), rechallenge with anti-PD-1 is generally not recommended. However, if the initial episode was low grade (grade 1-2), reinitiating therapy could be considered after a detailed discussion with the patient. Further investigation is needed to identify risk factors and to better define diagnostic criteria for pneumonitis.
Diarrhea/Colitis
Diarrhea and colitis are the most common severe irAEs experienced with ICIs, particularly with anti-CTLA-4-containing regimens. Diarrhea, which is defined as an increase in stool frequency, has overlapping features with colitis but is clinically distinct. Colitis specifically refers to the inflammation of the colon, which is manifested clinically as abdominal pain, diarrhea, and bloody stools. Regardless, the management of these adverse events is essentially identical. For this review, the use of the terms colitis and diarrhea will be interchangeable except in reference to clinical trial definitions.
A key component in the management of colitis is patient counseling prior to therapy initiation. Patients should report colitis symptoms rapidly, as delay in diagnosis and treatment often increases the risk of potentially morbid and/or even fatal toxicity. Upon presentation with diarrhea or other symptoms of colitis, a differential diagnosis of other potential etiologies must also be considered, which should include infections such as Clostridium difficile and other bacterial/viral pathogens. If other symptoms such as fever, chills, nausea, or vomiting suggest an infectious or alternative cause, they should be ruled out before or concurrently while initiating treatment for immune-related colitis.
In general, the diagnosis of immune-related colitis is largely clinical. If there is uncertainty with the diagnosis, a colonoscopy can be useful to direct management. Immune-related colitis can exhibit endoscopic findings ranging from normal to mild erythema to severe inflammation with biopsy findings including lamina propria expansion and neutrophilic cryptitis. 9 Histologically, findings between ipilimumab and anti-PD-1-related colitis have no clear distinctive features. Radiographic imaging such as CTwill often capture changes associated with colitis such as diffuse or segmental bowel wall thickening, but is neither routinely indicated nor specific for diagnosis. 10 The incidence and timing of colitis/diarrhea vary between the specific ICI used. Patients treated with anti-CTLA-4 agents, such as ipilimumab, experience severe (grade 3-4) colitis/diarrhea much more frequently (up to 10% vs. 1%-2%) and in a dose-dependent manner compared with patients who receive anti-PD-1 agents. [11] [12] [13] With dual blockade of CTLA-4 and PD-1 with ipilimumab and nivolumab, 9% of patients experienced severe diarrhea.
14 Although approximately only 10% of patients reported grade 3 to 4 diarrhea/ colitis, approximately 16% of patients discontinued combination therapy because of these symptoms. The timing of colitis is somewhat stereotypical with ipilimumab; onset is generally within 6 to 9 weeks of therapy initiation. 15 However, the incidence of diarrhea/ colitis becomes less predictable with anti-PD-1 agents. Retrospective studies by our group suggest that colitis related to anti-PD-1 generally occurs later but is widely variable. 16 Combined nivolumab/ ipilimumab-related colitis occurs with a more similar trajectory as ipilimumab alone but may occur even after a single dose.
Hepatitis
Hepatotoxicity related to immune therapy most frequently manifests as abnormal laboratory findings with rare instances of clinically significant symptoms. Immune-related hepatitis is diagnosed most commonly during routine laboratory checks, demonstrating elevations in serum aspartate aminotransferase and alanine aminotransferase with rare occurrences of elevation in bilirubin (usually concurrently when present). Patients will seldom have fevers, vomiting, or jaundice associated with hepatic inflammation. Imaging is unnecessary for diagnosis, but radiographic findings such as mild hepatomegaly, periportal edema, and periportal lymphadenopathy have been reported. 17 Liver biopsies demonstrate features such as severe panlobular hepatitis with prominent perivenular infiltrate with endothelialitis and primary biliary pattern with mild portal mononuclear infiltrate around proliferated bile ductules. 17, 18 As with colitis, appropriate suspicion for alternative etiologies should be maintained, including viral hepatitis, liver metastases, or other medication-induced hepatotoxicity (e.g., acetaminophen or statins).
The incidence of hepatitis varies with the ICI agent. Any grade of hepatitis occurred in up to 10% of patients with anti-CTLA-4 agents, 11, 13, 19 up to 7% with anti-PD1 agents, 20 and up to 33% with combination anti-CTLA-4 and anti-PD-1.
14 Timing of immune-related hepatitis is fairly characteristic with anti-CTLA-4-containing regimens, occurring most commonly 8 to 12 weeks after starting therapy, although onset can be variable in anti-PD-1-treated patients. 21 Given that immune-related hepatitis is most commonly diagnosed through laboratory findings, routine liver function laboratory tests should be performed prior to each dose of ICI.
Dermatologic
Dermatologic toxicities are among the most common irAEs noted in patients treated with ICIs. 22 With anti-PD-1 agents, 30% to 40% of patients will experience a dermatologic irAE of some grade during therapy. 22 These toxicities can include rash, pruritus, and vitiligo, which are fairly similar to those observed in patients treated with anti-CTLA-4 agents.
The incidence of all-grade rash in patients treated with anti-PD-1 agents is 14% to 17%, although the incidence of severe rash is less than 2%. Onset of rash generally occurs within 1 month of starting treatment but can occasionally arise much later into therapy. The rash most commonly occurs on the trunk or extremities and is characterized by erythematous macules, papules, and plaques. Pruritus is frequently also present. 23 Papulopustular rash, lichenoid dermatitis, bullous pemphigoid, Sweet syndrome, Stevens-Johnson syndrome, and toxic epidermal necrolysis have all been associated with anti-PD-1 therapy as well but are very rare. 22 Histologically, the most common finding is interface dermatitis. 22 For fulminant The
rash, those refractory to steroids, or blistering rash, biopsy is indicated to rule out more severe etiologies.
Other notable dermatologic irAEs include pruritus and vitiligo. Pruritus occurs in 13% to 20% of patients, with high-grade pruritus occurring in fewer than 2% of patients. Vitiligo occurs in up to 8% of patients, primarily those with melanoma. 23 Ultimately, most dermatologic toxicities are mild and resolve with topical treatment; however, refractory symptoms warrant evaluation by a dermatologist.
Although dermatologic symptoms can negatively influence patient quality of life, there is an association between developing a dermatologic toxicity from anti-PD-1 treatment and favorable patient outcomes. A similar finding was observed for targeted agents (sunitinib, erlotinib), where developing a rash portends a better prognosis. Several studies have suggested that developing either a rash or vitiligo while being treated with an anti-PD-1 agent is associated with improved progression-free and overall survival. 24, 25 Interestingly, vitiligo appears almost exclusively in melanoma patients, suggesting that T cells may be cross-reactive to pigment producing cells in both tumor and normal skin. Further investigation is needed to understand the relationship between dermatologic toxicity and response to treatment.
Endocrine
Approximately 1% to 2% of patients experience high-grade endocrinopathies that are immunotherapy related. The pituitary, thyroid, and adrenal glands can all be affected by checkpoint inhibitors, and with PD-1 inhibitors, thyroid dysfunction is the most common. Unlike other irAEs, endocrinopathies are generally irreversible. These events can also be difficult to diagnose because of nonspecific symptoms including fatigue, nausea, headache, and weakness. Evaluation can include vital signs and laboratory analysis with thyroid-stimulating hormone (TSH), free thyroxine (T4), adrenocorticotropic hormone, cortisol, follicle-stimulating hormone, luteinizing hormone, and growth hormone and a basic metabolic panel.
Diagnosing thyroid dysfunction from ICI may be somewhat complex. Hypothyroidism is the most common complication but may be preceded by a mild, subclinical thyroiditis. On occasion, a more clinically significant and symptomatic hyperthyroid state can occur that usually resolves with observation, but may occasionally require β-blockade or methimazole. Thyroid function should be assessed frequently, at least every other treatment. Primary versus secondary hypothyroidism should also be distinguished. Elevated TSH with a low free T4 is consistent with primary hypothyroidism. When TSH and free T4 are both low, this is consistent with a secondary process such as pituitary insufficiency. Hyperthyroidism, characterized by a low TSH and elevated free T4, can be seen transiently in thyroiditis or durably when associated with ICI-induced Graves disease. 26 Hypophysitis is a potentially dangerous event that is characterized by headache, fatigue, and weakness. Laboratory evaluation reveals low levels of some or all hormones made by the pituitary including TSH, adrenocorticotropic hormone, luteinizing hormone, follicle-stimulating hormone, and growth hormone. Brain magnetic resonance imaging may reveal pituitary inflammation or enlargement. 27 Hypophysitis is more common with anti-CTLA-4 agents alone or in combination with anti-PD-1 agents (1%-17%) than with anti-PD-1 monotherapy (1%-6%). 22, 28 Time of onset is generally 8 to 12 weeks after ICI. 28 Treatment with steroids may reverse the acute inflammation; however, for most cases, long-term hormone replacement is necessary. Adrenal insufficiency (AI) is another rare but life-threatening complication of ICI. This can be due to secondary AI in the setting of hypophysitis or less commonly primary AI. Signs of AI include hypotension, tachycardia, hyponatremia, and hyperkalemia. Stress dose steroids are given, and urgent evaluation by an endocrinologist is needed for highly symptomatic or unstable patients.
Rare Toxicities

Neurological Toxicities
Awide range of neurological symptoms have been contributed to anti-PD-1 therapy ranging from mild neuropathies to progressive debilitating syndromes. 29 The median onset of these neurological events has been reported fairly early, at approximately 6 to 7 weeks after treatment initiation, with resolution in 75% of patients after a median time of 4 to 5 weeks. Increased awareness and recognition by oncologists and neurologists of these potentially life-threatening irAEs are needed. In particular, progressive neuropathies (e.g., Guillain-Barré syndrome), aseptic meningitis/encephalitis, and neuromuscular conditions (e.g., myasthenia gravis) may cause highly morbid or fatal complications. 30, 31 Fortunately, the incidence of these events is low, up to 1% to 2% based on various studies. 29, 32 Consideration of alternative etiologies (e.g., spinal cord compression, brain metastases, cerebrovascular accident) is also imperative.
Ocular Toxicities
Immune toxicity of the eyes often present as intraocular inflammation or uveitis. This entity occurs in 1% of patients treated with anti-PD-1/L1 therapy but can have significant comorbidity if not treated. 33, 34 A consultation with ophthalmology is recommended to establish the diagnosis and facilitate prompt treatment with topical or oral corticosteroids.
Cardiac Toxicities
Clinically significant cardiovascular toxicities from anti-PD-1 monotherapy have ranged widely from cases of pericarditis, hypertension, atrial and ventricular arrhythmias, autoimmune myocarditis, and myocardial infarction with an incidence of approximately 1%. 35 The onset ranged widely from 2 to 17 weeks, and most cases improved or resolved with corticosteroids or supportive medication/care.
The combination of anti-PD-1 and CTLA-4 blockade has led to several reported cases of fatal immune-related myocarditis. 5 Pharmacovigilance studies revealed that the incidence of myocarditis is higher (0.27% vs. 0.06%) and more severe (0.17% vs. <0.01% fatal cases) in patients treated with combination of ipilimumab and nivolumab versus nivolumab alone. These cases were characterized by rapidly progressive and severe arrhythmias (including complete heart block and ventricular fibrillation). Thus, prompt recognition is necessary with urgent cardiology consultation and transfer to a cardiac care unit if available. We and others have also begun to screen patients weekly for troponin elevations during the first 3 to 6 weeks of combination PD-1/CTLA-4 therapy. Troponin seems to be the most sensitive marker of myocarditis, and elevated levels should be worked up with electrocardiogram, echocardiogram, and cardiology consult.
TREATMENT ALGORITHMS
The general guidelines for treatment of irAEs of anti-PD1/L1 therapies are largely based on clinical trial experience with ipilimumab and require familiarity with Common Terminology Criteria for Adverse Events version 4.03 (https://evs.nci.nih.gov/ftp1/ CTCAE/CTCAE_4.03_2010-06-14_QuickReference_8.5x11. pdf). 36 As a general principle, mild cases (grade 1) of irAEs generally require symptomatic management or monitoring, with no interruption of therapy (Fig. 2) . For patients who experience moderate irAEs (grade 2), treatment should be held until symptoms or toxicities improve to grade 1 or less. In some instances, low-dose corticosteroids (prednisone 0.5 mg/kg per day or equivalent) can be started if symptoms are bothersome or fail to improve within a week. For patients with more severe (grade 3 or 4) irAEs, treatment should usually be permanently discontinued. High-dose corticosteroids (prednisone 1-2 mg/kg per day or equivalent) should be commenced rapidly. Ambulatory, nontoxic patients can be considered for oral therapy, but more ill-appearing or dehydrated patients should be admitted for intravenous steroid administration. Once symptoms improve to grade 1 or less, a gradual taper of corticosteroids over at least a month should be initiated. If symptoms do not improve after 3 days with corticosteroids (especially intravenous), alternative immununosuppressants such as infliximab or mycophenolate mofetil should be strongly considered. Repeat dosing of such immununosuppressants may be necessary if symptoms persist. While the above information is a generalization, some important site-specific management for severe irAE is detailed below.
Pneumonitis
Grade 1 pneumonitis (imaging findings only) should be monitored closely. Grade 2 pneumonitis (mild symptoms), however, represents a departure from the aforementioned general algorithms in that prednisone 1 to 2 mg/kg should be initiated and pulmonary consultation should be considered. For patients with grade 3 to 4 pneumonitis, a bronchoscopy should be considered to rule out infectious causes prior to (or concurrently with) starting immunosuppression. Patients should be promptly hospitalized and started on high-dose corticosteroids (prednisone 1-2 mg/kg/daily or equivalent). Additional immunosuppression such as infliximab, mycophenolate mofetil, and cyclophosphamide should be considered. Once symptoms improve to grade 1 or less, a steroid taper of 4 to 6 weeks should be started.
Skin
Supportive measures are usually sufficient for low-grade rash and include topical emollients or low-potency corticosteroids, as well as oral antihistamines. If low-grade rash remains persistent and bothersome, a short burst of low-dose steroids may improve symptoms (e.g., prednisone 20-40 mg for 5 days). For grade 3 to 4 rash, high-dose oral corticosteroids should be started with consideration of alternative immunosuppressants such as infliximab, mycophenolate mofetil, or cyclophosphamide if symptoms do not begin to resolve. In rare instances, Stevens-Johnson syndrome and toxic epidermal necrolysis have been reported. 37 In such cases, prompt hospitalization and consultation by dermatology and critical care are necessary. Management relies heavily on supportive care with the consideration of increasing corticosteroids to prednisone equivalent of 2 mg/kg daily.
Diarrhea/Colitis
Antidiarrheals can be prescribed for low-grade diarrhea, but patients should be monitored and closely for worsening. For grade 3 to 4 colitis, along with high-dose corticosteroids, addition of infliximab (5 mg/kg) should be strongly considered if symptoms do not improve promptly (within 3 days). If symptoms persist after 2 weeks, another dose of infliximab at the same dose should be considered. For truly refractory cases, anti-integrin therapy (vedolizumab), complete bowel rest with total parenteral nutrition, or even colectomy has been reported, although close consultation with gastroenterologists and surgeons should be maintained. 38, 39 Once symptoms improve to grade 1 or less, a steroid taper of 4 to 6 weeks should be started. During the steroid taper, colitis flares can occur. In these instances, increasing steroids or consideration of infliximab may be indicated.
Hepatitis
Patients with grade 3 to 4 hepatitis should receive high-dose corticosteroids. If liver function does not improve or relapses during a taper, mycophenolate mofetil (500-1000 mg every 12 hours) or tacrolimus should be started. Infliximab is contraindicated in cases of hepatitis because of its hepatotoxic nature. Once liver functions begin to improve, a gradual taper should begin with a taper of mycophenolate mofetil until prednisone is tapered to 10 mg per day. Rarely, patients may have steroid-and mycophenolaterefractory hepatitis. Improvement with the addition of antithymocyte globulin at 1.5 mg/kg for 2 consecutive days with steroids and mycophenolate has been reported. 40 
Cardiac
The optimal treatment for immune myocarditis is not clear. Treatment regimens should certainly include high-dose corticosteroids. Alternative immunosuppressants such as infliximab, antithymocyte globulin, mycophenolate mofetil, and tacrolimus should be considered in patients who do not respond to corticosteroids or have severe disease. Supportive management for arrhythmias and potentially decreased ejection fraction is also a cornerstone of management.
Neurologic
Treatment for neurological toxicities should be initiated promptly and typically includes high-dose systemic corticosteroids. Neurological consultation should also be obtained to aid in clarifying the diagnosis. Condition-specific treatments may also be beneficial, including intravenous immunoglobulin or plasmapheresis. 41 
CONCLUSIONS
In summary, PD-1/PD-L1 inhibitors have rapidly changed treatment algorithms for numerous malignancies. Despite their impressive response rates and relative tolerability, checkpoint inhibitors can result in both unique and severe toxicities. It is important that providers are aware of the range of irAEs that patients can experience as well as their presentation, natural history, and treatment. Multidisciplinary management with endocrine, gastrointestinal, or pulmonary specialists may be indicated in many cases. Further study is needed to determine risk factors that predispose patients to toxicity and how to optimally manage irAEs.
